Saroglitazar magnesium improves lipid parameters in patients with non-alcoholic fatty liver disease / non-alcoholic steatohepatitis

Background and Aims: Dyslipidemia in patients with non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH) may increase the risk of cardiovascular disease (CVD). Saroglitazar Magnesium (SARO), a novel dual peroxisome proliferator activated receptor α/γ agonist, has been shown in clinical studies to improve atherogenic dyslipidemia in patients with diabetic dyslipidemia.